EMA Review of Apitegromab in Spinal SMA Delayed
EMA Review of Apitegromab in Spinal muscular atrophy is running past the July 2026 CHMP meeting window while regulators wait on manufacturing-site classification. Scholar Rock said on 20 July 2026 that Europe’s opinion timing now depends on FDA’s update for the Catalent Indiana fill-finish facility named in the marketing authorisation application.
Contents11 sections
Key Takeaways
- Scholar Rock disclosed on 20 July 2026 that a CHMP opinion on apitegromab for SMA is expected only after Catalent Indiana’s FDA inspection classification is resolved or a second fill-finish site is added to the MAA.
- EMA is reviewing the MAA; the July 2026 CHMP meeting began before that FDA classification update was available.
- Apitegromab already holds EU orphan designation (EU/3/18/2115) for SMA; orphan status is not the same as marketing authorisation.
- The US BLA has a PDUFA date of 30 September 2026.
Apitegromab EMA review at a glance
| Field | Detail |
|---|---|
| Drug | Apitegromab (anti-promyostatin monoclonal antibody; SRK-015) |
| Company | Scholar Rock (NASDAQ: SRRK) |
| Indication sought | Spinal muscular atrophy (children and adults) |
| EU procedure | Marketing authorisation application under EMA review |
| Delay driver | FDA inspection classification of Catalent Indiana fill-finish site |
| EU orphan ID | EU/3/18/2115 (granted 14 December 2018) |
| US PDUFA date | 30 September 2026 |
| Pivotal trial | SAPPHIRE Phase 3 (NCT05156320) |
What did Scholar Rock say on 20 July 2026?
As the July 2026 CHMP meeting opened, Scholar Rock said EMA is reviewing the apitegromab MAA for children and adults with SMA and is awaiting an FDA update on the inspection classification of Catalent Indiana LLC (part of Novo Nordisk) after an April 2026 general site inspection.
The company said a CHMP opinion would be expected later in 2026 if FDA reclassifies Catalent Indiana. If the site is not reclassified, Scholar Rock said it will work with EMA to advance the MAA using a second fill-finish facility already included in the US BLA. The update is documented in Scholar Rock’s 20 July 2026 Business Wire release.
Is this a clinical hold or a manufacturing-clock issue?
On the company’s description, the timing issue is manufacturing-site classification for a fill-finish plant listed in the European dossier. Scholar Rock did not announce a new EMA clinical deficiency, a negative benefit-risk finding, or withdrawal of the MAA.
That distinction matters for EU SMA clinics waiting on a potential myostatin-pathway adjunct. Manufacturing inspection outcomes can delay CHMP opinions even when clinical packages continue under review. Board Chair and CEO David L. Hallal said the company remains confident it can advance the MAA either with Catalent Indiana or by including the second fill-finish facility.
What EU regulatory footprint already exists for apitegromab?
Apitegromab is not newly appearing before EMA. The European Commission granted orphan designation EU/3/18/2115 on 14 December 2018 for human anti-promyostatin monoclonal antibody (also known as SRK-015) for SMA. Sponsorship later transferred to Scholar Rock Netherlands B.V.
Orphan designation supports development incentives; it does not authorise marketing. The current news is about MAA opinion timing during active review, not about orphan status itself. The designation record is on the EMA orphan designation page EU/3/18/2115.
How does the clinical package sit behind the MAA?
Apitegromab’s Phase 3 SAPPHIRE trial (NCT05156320) evaluated efficacy and safety in later-onset SMA patients receiving background nusinersen or risdiplam. ClinicalTrials.gov lists the study as completed, with about 188 participants and a design spanning main efficacy and exploratory age subpopulations.
That registry record is useful context for why European review is underway, but it does not resolve the manufacturing-site clock described on 20 July. See ClinicalTrials.gov NCT05156320 (SAPPHIRE) for the trial identity and status fields.
What are the near-term EU and US checkpoints?
For Europe, the next decisive signals are an FDA classification update for Catalent Indiana or an EMA procedural step confirming a second fill-finish facility in the MAA. Scholar Rock said it will provide a further update on its second-quarter earnings call on 6 August 2026.
For the United States, the company reiterated a 30 September 2026 PDUFA action date for the BLA that already includes the second fill-finish facility. EU and US clocks are therefore linked through shared manufacturing geography even though the procedures remain separate.
What remains unproven
As of the 20 July 2026 company wire, there is no public CHMP positive or negative opinion on apitegromab, no European Commission marketing authorisation, and no final FDA classification outcome for Catalent Indiana disclosed in that release. Readers should not treat the delay update as an approval, a refusal, or a clinical failure.
Until EMA publishes a procedural announcement or CHMP opinion, the verified European facts are the active MAA review described by the sponsor, the orphan designation record, and the SAPPHIRE trial identity.
Related NovaPharma coverage
- Vanda Pharmaceuticals EMA orphan drug designation opinion
- PRAC June 2026 highlights: valproate signal review
- EU Commission and EMA 2026 drug report key findings
Frequently Asked Questions
Why is the EMA review of apitegromab delayed?
Scholar Rock said on 20 July 2026 that EMA is awaiting an FDA inspection-classification update for the Catalent Indiana LLC fill-finish facility included in the European marketing authorisation application. The company framed the timing issue as manufacturing-site status, not a new clinical efficacy concern.
When could CHMP issue an opinion on apitegromab?
If FDA reclassifies Catalent Indiana, Scholar Rock expects a CHMP opinion later in 2026. If not, the company said it will work with EMA to advance the MAA using a second fill-finish facility already included in the US BLA.
What is the US timeline for apitegromab?
Scholar Rock said the US biologics license application remains under FDA review with a Prescription Drug User Fee Act action date of 30 September 2026.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for apitegromab.
Unlock full calendar →This article follows our editorial standards. Report a correction via editorial contact.
